Exploratory double-blind comparison of inspiratory capacity and FEV1 with indacaterol vs placebo and open-label formoterol in COPD

Phase 2, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoints: Time-course of FEV1 and IC compared to placebo and Responsiveness and variability of mean maximal change in percent predicted FEV1 vs IC from baseline. Started Aug 2006; status: completed.